Sakar Healthcare Intrinsic Value
Sakar Healthcare (SAKAR) median intrinsic value is ₹214.55 from 9 valuation models (range ₹186–₹309), vs current price ₹618.60 — -65.3% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit SAKAR share price.
SAKAR Valuation Methods Summary — DCF, Graham Number & P/E
Sakar Healthcare intrinsic value across 9 models vs current price ₹618.60 — upside/downside and value range per method. Browse Sakar Healthcare financial data for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹185.58 | ₹148.46 - ₹222.70 | -70.0% | EPS: ₹8.12, Sector P/E: 22x |
| Book Value Method | asset | ₹260.00 | ₹234.00 - ₹286.00 | -58.0% | Book Value/Share: ₹130.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹214.55 | ₹193.10 - ₹236.01 | -65.3% | Revenue/Share: ₹107.27, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹247.44 | ₹222.70 - ₹272.18 | -60.0% | EBITDA: ₹52.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹247.44 | ₹197.95 - ₹296.93 | -60.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹185.58 | ₹167.02 - ₹204.14 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹185.58 | ₹167.02 - ₹204.14 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹309.30 | ₹278.37 - ₹340.23 | -50.0% | ROE: 7.0%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹185.58 | ₹167.02 - ₹204.14 | -70.0% | EPS: ₹8.12, BVPS: ₹130.00 |
SAKAR Intrinsic Value vs Market Price — All Valuation Models
Sakar Healthcare fair value range ₹186–₹309 vs current market price ₹618.60 across 9 valuation models. Compare with SAKAR stock valuation models to assess whether the stock is under or overvalued.
SAKAR Intrinsic Value Analysis — Undervalued or Overvalued?
Sakar Healthcare median intrinsic value ₹214.55, current price ₹618.60 — Trading Above Calculated Value by 65.3%, margin of safety -100.0%.
What is the intrinsic value of SAKAR?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Sakar Healthcare (SAKAR) is ₹214.55 (median value). With the current market price of ₹618.60, this represents a -65.3% variance from our estimated fair value.
The valuation range spans from ₹185.58 to ₹309.30, indicating ₹185.58 - ₹309.30.
Is SAKAR undervalued or overvalued?
Based on our multi-method analysis, Sakar Healthcare (SAKAR) appears to be trading above calculated value by approximately 65.3%.
SAKAR Financial Health — Key Ratios vs Industry Benchmarks
Sakar Healthcare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.33 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 7.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 20.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.57x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
SAKAR Cash Flow Quality — Operating & Free Cash Flow
Sakar Healthcare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹34 Cr | ₹19 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹25 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹33 Cr | ₹-4 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹36 Cr | ₹-9 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹15 Cr | ₹-9 Cr | Positive Operating Cash Flow | 6/10 |